The potential of immunotherapy is yet unfolding, with novel immune targets such as LAG3 or VISTA being evaluated, and CAR-T cell therapy showing the first promising results in gastric and hepatocellular carcinomas. Here, VSIR is linked to hepatocellular carcinoma.